RxFunction, Inc. — SEC Form D Filing

RxFunction, Inc. filed an SEC Form D on October 14, 2026, reporting $4.01M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
October 14, 2026
Amount reported
$4.01M
Round stage
Seed
Industry
Medical Devices
Website
https://rxfunction.com/

What the company does

Securities: The underlying offering is complete and this amendment to the original Form D covers only the Common Stock issuable upon exercise of warrants sold in the underlying offerings.. Exemption: Rule 506(b). Incorporated: MINNESOTA

Problem

Patients with sensory peripheral neuropathy often experience numb feet, struggle with gait and balance, and face a high risk of falls due to lost foot sensation.

Solution

RxFunction provides Walkasins, a wearable lower limb sensory prosthetic device that delivers mechanical tactile stimuli to the leg, replacing lost foot sensation to improve balance, gait, and reduce fall risk for individuals with peripheral neuropathy.

Why now

Advances in wearable technology and sensory prosthetics, combined with an aging population and increased awareness of fall prevention in healthcare, create a demand for effective, non-invasive solutions for neurological conditions.

Verdict

Investors backed this round because the solution directly addressed a high-cost, high-frequency problem in an aging demographic with a clear, non-invasive device. This cleared because it offered a tangible, direct sensory replacement for a known deficit, not because it promised novel neuroplasticity or broad neurological restoration. The implicit bet was on market adoption driven by a simple functional improvement, rather than on groundbreaking scientific discovery. Upside was limited by the device's specific application and the regulatory and reimbursement hurdles typical for specialized medical devices, rather than a platform play.

Source: SEC EDGAR Form D filing